Why should they? They already did..... they're likely doing exactly what they said they would do. Which, imo, will lead to this stock returning to previous highs, soon enough. Let the price keep dropping..... I'll buy more with confidence.
"We plan to further analyze the data and provide an update after we have discussed the data and our plans for a path forward with the regulatory agencies,” said Guy Macdonald, President and CEO of Tetraphase. “We previously announced positive data from the IGNITE1 phase 3 clinical trial of eravacycline administered intravenously in complicated intra-abdominal infections which did meet its primary endpoint, demonstrating high cure rates in prevalent Gram-negative pathogens and a favorable safety profile.”
Macdonald added, “We continue to believe that eravacycline can benefit patients with serious infections, particularly those caused by difficult-to-treat Gram-negative bacteria.”
News 
Market Data 
Discover 
